These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 27494877)

  • 1. FOXM1 confers resistance to gefitinib in lung adenocarcinoma via a MET/AKT-dependent positive feedback loop.
    Wang Y; Zhang W; Wen L; Yang H; Wen M; Yun Y; Zhao L; Zhu X; Tian L; Luo E; Li Y; Liu W; Wen N
    Oncotarget; 2016 Sep; 7(37):59245-59259. PubMed ID: 27494877
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FoxM1 promotes epithelial-mesenchymal transition, invasion, and migration of tongue squamous cell carcinoma cells through a c-Met/AKT-dependent positive feedback loop.
    Yang H; Wen L; Wen M; Liu T; Zhao L; Wu B; Yun Y; Liu W; Wang H; Wang Y; Wen N
    Anticancer Drugs; 2018 Mar; 29(3):216-226. PubMed ID: 29360662
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HGF/Met and FOXM1 form a positive feedback loop and render pancreatic cancer cells resistance to Met inhibition and aggressive phenotypes.
    Cui J; Xia T; Xie D; Gao Y; Jia Z; Wei D; Wang L; Huang S; Quan M; Xie K
    Oncogene; 2016 Sep; 35(36):4708-18. PubMed ID: 26876216
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reciprocal positive regulation between Cx26 and PI3K/Akt pathway confers acquired gefitinib resistance in NSCLC cells via GJIC-independent induction of EMT.
    Yang J; Qin G; Luo M; Chen J; Zhang Q; Li L; Pan L; Qin S
    Cell Death Dis; 2015 Jul; 6(7):e1829. PubMed ID: 26203858
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activation of an AKT/FOXM1/STMN1 pathway drives resistance to tyrosine kinase inhibitors in lung cancer.
    Li M; Yang J; Zhou W; Ren Y; Wang X; Chen H; Zhang J; Chen J; Sun Y; Cui L; Liu X; Wang L; Wu C
    Br J Cancer; 2017 Sep; 117(7):974-983. PubMed ID: 28850563
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The PI3K/AKT pathway promotes gefitinib resistance in mutant KRAS lung adenocarcinoma by a deacetylase-dependent mechanism.
    Jeannot V; Busser B; Brambilla E; Wislez M; Robin B; Cadranel J; Coll JL; Hurbin A
    Int J Cancer; 2014 Jun; 134(11):2560-71. PubMed ID: 24374738
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FoxM1 promotes breast tumorigenesis by activating PDGF-A and forming a positive feedback loop with the PDGF/AKT signaling pathway.
    Yu G; Zhou A; Xue J; Huang C; Zhang X; Kang SH; Chiu WT; Tan C; Xie K; Wang J; Huang S
    Oncotarget; 2015 May; 6(13):11281-94. PubMed ID: 25869208
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GLRX inhibition enhances the effects of geftinib in EGFR-TKI-resistant NSCLC cells through FoxM1 signaling pathway.
    Wang L; Liu J; Liu J; Chen X; Chang M; Li J; Zhou J; Bai C; Song Y
    J Cancer Res Clin Oncol; 2019 Apr; 145(4):861-872. PubMed ID: 30661098
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MiR-128 reverses the gefitinib resistance of the lung cancer stem cells by inhibiting the c-met/PI3K/AKT pathway.
    Jiang J; Feng X; Zhou W; Wu Y; Yang Y
    Oncotarget; 2016 Nov; 7(45):73188-73199. PubMed ID: 27690301
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blocking the PI3K/AKT and MEK/ERK signaling pathways can overcome gefitinib-resistance in non-small cell lung cancer cell lines.
    Li H; Schmid-Bindert G; Wang D; Zhao Y; Yang X; Su B; Zhou C
    Adv Med Sci; 2011; 56(2):275-84. PubMed ID: 22037177
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FoxM1 mediated resistance to gefitinib in non-small-cell lung cancer cells.
    Xu N; Zhang X; Wang X; Ge HY; Wang XY; Garfield D; Yang P; Song YL; Bai CX
    Acta Pharmacol Sin; 2012 May; 33(5):675-81. PubMed ID: 22447226
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations.
    Yano S; Wang W; Li Q; Matsumoto K; Sakurama H; Nakamura T; Ogino H; Kakiuchi S; Hanibuchi M; Nishioka Y; Uehara H; Mitsudomi T; Yatabe Y; Nakamura T; Sone S
    Cancer Res; 2008 Nov; 68(22):9479-87. PubMed ID: 19010923
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Norcantharidin combined with EGFR-TKIs overcomes HGF-induced resistance to EGFR-TKIs in EGFR mutant lung cancer cells via inhibition of Met/PI3k/Akt pathway.
    Wu H; Fan F; Liu Z; Shen C; Wang A; Lu Y
    Cancer Chemother Pharmacol; 2015 Aug; 76(2):307-15. PubMed ID: 26063323
    [TBL] [Abstract][Full Text] [Related]  

  • 14. METTL1/FOXM1 promotes lung adenocarcinoma progression and gefitinib resistance by inhibiting PTPN13 expression.
    Peng W; Fu J; Zhou L; Duan H
    Cancer Med; 2024 Jul; 13(13):e7420. PubMed ID: 38967523
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activation of AKT/AP1/FoxM1 signaling confers sorafenib resistance to liver cancer cells.
    Yan D; Yan X; Dai X; Chen L; Sun L; Li T; He F; Lian J; Cai W
    Oncol Rep; 2019 Aug; 42(2):785-796. PubMed ID: 31233189
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.
    Engelman JA; Zejnullahu K; Mitsudomi T; Song Y; Hyland C; Park JO; Lindeman N; Gale CM; Zhao X; Christensen J; Kosaka T; Holmes AJ; Rogers AM; Cappuzzo F; Mok T; Lee C; Johnson BE; Cantley LC; Jänne PA
    Science; 2007 May; 316(5827):1039-43. PubMed ID: 17463250
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acquired resistance to cetuximab is mediated by increased PTEN instability and leads cross-resistance to gefitinib in HCC827 NSCLC cells.
    Kim SM; Kim JS; Kim JH; Yun CO; Kim EM; Kim HK; Solca F; Choi SY; Cho BC
    Cancer Lett; 2010 Oct; 296(2):150-9. PubMed ID: 20444542
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Sensitivity of two cell lines with acquired resistance to gefitinib to several chemotherapeutic drugs].
    Deng QF; Su B; Zhao YM; Zhou CC
    Zhonghua Zhong Liu Za Zhi; 2008 Nov; 30(11):813-6. PubMed ID: 19173824
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Capilliposide from Lysimachia capillipes inhibits AKT activation and restores gefitinib sensitivity in human non-small cell lung cancer cells with acquired gefitinib resistance.
    Zhang SR; Xu YS; Jin E; Zhu LC; Xia B; Chen XF; Li FZ; Ma SL
    Acta Pharmacol Sin; 2017 Jan; 38(1):100-109. PubMed ID: 27840409
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FoxM1 inhibition enhances chemosensitivity of docetaxel-resistant A549 cells to docetaxel via activation of JNK/mitochondrial pathway.
    Wang K; Zhu X; Zhang K; Zhu L; Zhou F
    Acta Biochim Biophys Sin (Shanghai); 2016 Sep; 48(9):804-9. PubMed ID: 27521795
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.